Dierssen M, Flórez J, Hurlé M A
Departamento de Fisiología y Farmacología, Universidad de Cantabria, Santander, Spain.
Naunyn Schmiedebergs Arch Pharmacol. 1990 Nov;342(5):559-65. doi: 10.1007/BF00169046.
The study was aimed at elucidating the possible participation of L-type Ca2+ channel in the acute analgesic effect of an opiate and the development of tolerance to this action. Sufentanil, a selective mu agonist, and two dihydropyridines, the Ca2+ antagonist nimodipine and the Ca2+ agonist Bay K 8644, were selected. The tailflick test was used to assess the nociceptive threshold. In naive rats, nimodipine (200 micrograms/kg) potentiated the analgesic effect of sufentanil reducing the ED50 from 0.26 to 0.08 microgram/kg. Similar results were observed with its (-)-enantiomer Bay N 5248, while the (+) enantiomer Bay N 5247 was ineffective. Tolerance to the opiate was induced by chronic subcutaneous administration of sufentanil with minipumps (2 micrograms/h, 7 days). In these conditions the dose-response curve to sufentanil was displaced to the right and the ED50 was increased to 1.49 micrograms/kg. In tolerant rats, nimodipine preserved its potentiating ability and prevented the displacement to the right of the sufentanil dose response-curve (ED50 = 0.48 microgram/kg). When nimodipine was pumped (1 microgram/h, 7 days) concurrently with sufentanil, the development of tolerance to the opioid was not disturbed. However, the expression of tolerance was abolished and even the effect of acutely administered sufentanil was markedly potentiated (ED50 = 0.03 microgram/kg). Similar experiments were performed with Bay K 8644. In naive rats, Bay K 8644 at a low dose (20 micrograms/kg) that behaves as a calcium agonist, antagonized the analgesic effect of sufentanil (ED50 = 0.58 microgram/kg), whereas at a high dose (200 micrograms/kg) it potentiated this action (ED50 = 0.15 microgram/kg).(ABSTRACT TRUNCATED AT 250 WORDS)
该研究旨在阐明L型钙通道在阿片类药物急性镇痛作用及其耐受性形成过程中可能发挥的作用。选用了选择性μ受体激动剂舒芬太尼,以及两种二氢吡啶类药物,钙拮抗剂尼莫地平和钙激动剂Bay K 8644。采用甩尾试验评估痛觉阈值。在未用药的大鼠中,尼莫地平(200微克/千克)增强了舒芬太尼的镇痛作用,使半数有效量(ED50)从0.26微克/千克降至0.08微克/千克。其(-)-对映体Bay N 5248也观察到类似结果,而(+)对映体Bay N 5247则无效。通过微型泵皮下持续给药舒芬太尼(2微克/小时,7天)诱导对阿片类药物的耐受性。在这些条件下,舒芬太尼的剂量-反应曲线右移,ED50增加至1.49微克/千克。在产生耐受性的大鼠中,尼莫地平保留了其增强作用,并阻止了舒芬太尼剂量-反应曲线右移(ED50 = 0.48微克/千克)。当尼莫地平与舒芬太尼同时通过泵给药(1微克/小时,7天)时,对阿片类药物耐受性的形成未受干扰。然而,耐受性的表现被消除,甚至急性给药舒芬太尼的作用也显著增强(ED50 = 0.03微克/千克)。用Bay K 8644进行了类似实验。在未用药的大鼠中,低剂量(20微克/千克)表现为钙激动剂的Bay K 8644拮抗了舒芬太尼的镇痛作用(ED50 = 0.58微克/千克),而高剂量(200微克/千克)则增强了该作用(ED50 = 0.15微克/千克)。(摘要截断于250字)